It is intended to provide a drug of a novel type for restoring the corneal sense after keratotomy or improving the dry eye symptom. Application of a somatostatin receptor agonist is useful in improving corneal dysesthesia following cataract operation, following LASIK operation, or associating corneal nerve degeneration such as neuroparalytic keratitis, corneal ulcer or diabetic keratopathy, and the dry eye symptom.
